Your browser doesn't support javascript.
loading
Three-Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma.
Tan, Marcus Chun Jin; Ong, Chee Wui; Aquino, Maria Cecilia; Lun, Katherine Wanxian; Sng, Chelvin Cheryl Agnes; Lim, Dawn Ka Ann; Loon, Seng Chee; Koh, Victor Teck Chang; Chew, Paul Tec Kuan.
Afiliación
  • Tan MCJ; Department of Ophthalmology, National University Hospital, National University Health System.
  • Ong CW; Centre for Innovation and Precision Eye Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Aquino MC; Department of Ophthalmology, National University Hospital, National University Health System.
  • Lun KW; Department of Ophthalmology, National University Hospital, National University Health System.
  • Sng CCA; Department of Ophthalmology, National University Hospital, National University Health System.
  • Lim DKA; Department of Ophthalmology, National University Hospital, National University Health System.
  • Loon SC; Department of Ophthalmology, National University Hospital, National University Health System.
  • Koh VTC; Department of Ophthalmology, National University Hospital, National University Health System.
  • Chew PTK; Department of Ophthalmology, National University Hospital, National University Health System.
J Glaucoma ; 33(7): 478-485, 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38506749
ABSTRACT
PRCIS In our case series, the 3-year failure for Paul Glaucoma Implant (PGI) implantation was 14.6%. At 3 years postoperatively, there was a significant reduction in mean intraocular pressure (IOP) and the number of glaucoma medications used.

OBJECTIVE:

To determine the 3-year efficacy and safety of the PGI, a novel glaucoma tube shunt in patients with glaucoma.

METHODS:

Retrospective review of all patients who had undergone PGI implantation in a single tertiary institution in Singapore between May 1, 2017 and January 1, 2022. Data were extracted from electronic health records (Computerized Patient Support System 2 and Epic). The primary outcome measure was failure, defined as IOP >18 mm Hg or <6 mm Hg on 2 consecutive visits after 3 months, reoperation for IOP-related indication, explantation of implant, or loss of light perception vision. Complete success was defined as the absence of failure without medications at 36 months, and qualified success similarly, but with medications. Postoperative mean IOP, mean number of IOP-lowering medications used, and visual acuity were also assessed.

RESULTS:

Forty-eight eyes in 48 patients were identified. Thirty-one patients (64.6%) had primary open angle and angle closure glaucoma, and 18 (37.5%) had previous existing tube implants or trabeculectomy. At 3 years postoperatively, 7 cases (14.6%) fulfilled the criteria for failure and 36 (75%) met the criteria for complete success. The mean IOP at 36 months was 14.9 ± 4.11 mm Hg, from the mean preoperative IOP of 20.6 ± 6.13 mm Hg ( P < 0.001). The mean number of IOP-lowering medications used was reduced from 3.13 ± 0.959 preoperatively to 0.167 ± 0.476 at 36 months ( P < 0.001). The most common postoperative complication was hypotony (n = 17, 35.4%), of which the majority were self-limiting, followed by hyphema (n = 5, 10.4%) and tube exposure (n = 4, 8.3%).

CONCLUSION:

The PGI demonstrated sustained IOP reduction and a reduction of medication burden at 3 years postoperatively.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tonometría Ocular / Agudeza Visual / Implantes de Drenaje de Glaucoma / Presión Intraocular Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Glaucoma Asunto de la revista: OFTALMOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tonometría Ocular / Agudeza Visual / Implantes de Drenaje de Glaucoma / Presión Intraocular Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Glaucoma Asunto de la revista: OFTALMOLOGIA Año: 2024 Tipo del documento: Article